Comparison
Sermorelin vs Tesamorelin
Two GHRH analogs with different track records
The key difference
Both mimic growth-hormone-releasing hormone. Sermorelin is a short fragment of natural GHRH; tesamorelin is a stabilized full-length analog.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Evidence | Human clinical trials | FDA-approved drug |
| Status | Not currently marketed as an FDA-approved product. | Prescription drug. FDA-approved for one specific indication. |
| Also known as | — | Egrifta |
| Researched for | Muscle & body composition, Sleep, Longevity | Muscle & body composition, Weight & metabolism |
| Evidence strength | Human clinical trials | FDA-approved drug |
What else differs
- Tesamorelin is FDA-approved for one specific use: reducing excess abdominal fat in HIV-associated lipodystrophy.
- Sermorelin was once approved for pediatric growth hormone deficiency, but the branded product was discontinued.
Bottom line
Same mechanism family; tesamorelin has the current approval and stronger recent data.
Read the research
Sermorelin on PubMed →
Tesamorelin on PubMed →
Educational content, not medical advice. This page does not recommend or dose any substance. Compounds that are not FDA-approved have not been established as safe or effective in people.